References
- Dillaha C. J., Jansen G. T., Honeycutt W. M., Holt C. A. Arch. Dermatol. 1963; 88: 247
- Dillaha C. J., Jansen G. T., Honeycutt W. M., Holt C. A. Arch. Dermatol. 1965; 92: 410
- Tsuji T., Sugai T. Arch. Dermatol. 1972; 105: 208
- Epstein E. Arch. Dermatol. 1985; 121: 207
- Touitou E., Abed L. Int. J. Pharm. 1985; 27: 89
- Goodman M., Barry B. W. J. Invest. Dermatol. 1988; 91: 323
- Beall H., Prankerd R. J., Sloan K. B. Int. J. Pharm. 1994; 111: 223
- Sloan K. B., Getz J. J., Beall H. D., Prankerd R. J. Int. J. Pharm. 1993; 93: 27
- Mollgaard B., Hoelgaard A., Bundgaard H. Int. J. Pharm. 1982; 12: 153
- Sloan K. B., Sherertz E. F., McTiernan R. G. Int. J. Pharm. 1988; 44: 87
- Buur A., Bundgaard H. Int. J. Pharm. 1984; 21: 349
- Tada M. Chem. Lett. 1975; 129
- Beall H. D., Prankerd R. J., Todaro L. J., Sloan K. B. Pharm. Res. 1993; 10: 905
- Beall H. D. Bioreversible derivatives of 5-fluorouracil (5-FU): Improving dermal and transdermal delivery with prodrugs. Ph.D. dissertation, University of Florida, Gainesville December, 1991
- Bodor N., Sloan K. B., Kuo Y., Higuchi T. J. Pharm. Sci. 1978; 67: 1045
- Streitwieser A., Heathcock C. H., Kosower E. M. Introduction to Organic Chemistry, 4th ed. Macmillan Publishing Co., New York 1992; 522
- Charton M. Design of Biopharmaceutical Properties Through Prodrugs and Analogs, E. B. Roche. American Pharmaceutical Association, Washington, D.C. 1977; 228
- Buur A., Bundgaard H., Falch E. Int. J. Pharm. 1985; 24: 43
- Exner O. Correlation Analysis of Chemical Data. Plenum Press, New York 1988; 154
- Hudson R. F., Moss G. E. J. Chem. Soc. 1962; 5157
- Gold V. Trans. Faraday Soc. 1948; 44: 506
- Sloan K. B., Beall H. D., Weimar W. R., Villanueva R. Int. J. Pharm. 1991; 73: 97
- Staab H. A. Angew. Chem. Int. Ed. Engl. 1962; 1: 351